Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Numerous biological pathways are affected in renal cell carcinoma and the introduction of targeted agents has improved the survival of patients with advanced and metastatic disease. Durable and long-lasting cure is rarely achieved, and in select cases, the excision of metastatic deposits has shown to increase survival. Clinical trials of targeted agents are being explored as neoadjuvant and adjuvant therapies with the role of metastasectomy evolving in the treatment paradigm. This review examines published reports of metastasectomy and its developing role in the era of targeted therapy. A Medline search was conducted using keywords "metastasectomy," "renal cell carcinoma," and "targeted therapy," and selected articles are discussed by examining prognostic stratification and metastasectomy in major anatomic regions. Most published reports span earlier periods of immunotherapy and chemotherapy, and henceforth, discussions are in historical context in this review. Although there is lack of Level 1 evidence, reports have suggested the prognostic value and survival benefit for metastasectomy in lesions that are amenable to complete resection after longer disease-free intervals in carefully selected patients with adequate performance status. Therefore, the role of metastasectomy must be further elucidated in the era of targeted therapy.

Original languageEnglish (US)
Pages (from-to)631-642
Number of pages12
JournalWorld journal of urology
Volume32
Issue number3
DOIs
StatePublished - May 2014

Fingerprint

Metastasectomy
Renal Cell Carcinoma
Survival
Therapeutics
Neoadjuvant Therapy
Immunotherapy
Clinical Trials
Drug Therapy

Keywords

  • Kidney cancer
  • Metastasectomy
  • Renal cell carcinoma
  • Targeted therapy

ASJC Scopus subject areas

  • Urology

Cite this

Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. / Kim, Dae Y.; Karam, Jose A.; Wood, Christopher G.

In: World journal of urology, Vol. 32, No. 3, 05.2014, p. 631-642.

Research output: Contribution to journalArticle

@article{c901b27b9f934fe690ad74a08964b0b6,
title = "Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy",
abstract = "Numerous biological pathways are affected in renal cell carcinoma and the introduction of targeted agents has improved the survival of patients with advanced and metastatic disease. Durable and long-lasting cure is rarely achieved, and in select cases, the excision of metastatic deposits has shown to increase survival. Clinical trials of targeted agents are being explored as neoadjuvant and adjuvant therapies with the role of metastasectomy evolving in the treatment paradigm. This review examines published reports of metastasectomy and its developing role in the era of targeted therapy. A Medline search was conducted using keywords {"}metastasectomy,{"} {"}renal cell carcinoma,{"} and {"}targeted therapy,{"} and selected articles are discussed by examining prognostic stratification and metastasectomy in major anatomic regions. Most published reports span earlier periods of immunotherapy and chemotherapy, and henceforth, discussions are in historical context in this review. Although there is lack of Level 1 evidence, reports have suggested the prognostic value and survival benefit for metastasectomy in lesions that are amenable to complete resection after longer disease-free intervals in carefully selected patients with adequate performance status. Therefore, the role of metastasectomy must be further elucidated in the era of targeted therapy.",
keywords = "Kidney cancer, Metastasectomy, Renal cell carcinoma, Targeted therapy",
author = "Kim, {Dae Y.} and Karam, {Jose A.} and Wood, {Christopher G.}",
year = "2014",
month = "5",
doi = "10.1007/s00345-014-1293-6",
language = "English (US)",
volume = "32",
pages = "631--642",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy

AU - Kim, Dae Y.

AU - Karam, Jose A.

AU - Wood, Christopher G.

PY - 2014/5

Y1 - 2014/5

N2 - Numerous biological pathways are affected in renal cell carcinoma and the introduction of targeted agents has improved the survival of patients with advanced and metastatic disease. Durable and long-lasting cure is rarely achieved, and in select cases, the excision of metastatic deposits has shown to increase survival. Clinical trials of targeted agents are being explored as neoadjuvant and adjuvant therapies with the role of metastasectomy evolving in the treatment paradigm. This review examines published reports of metastasectomy and its developing role in the era of targeted therapy. A Medline search was conducted using keywords "metastasectomy," "renal cell carcinoma," and "targeted therapy," and selected articles are discussed by examining prognostic stratification and metastasectomy in major anatomic regions. Most published reports span earlier periods of immunotherapy and chemotherapy, and henceforth, discussions are in historical context in this review. Although there is lack of Level 1 evidence, reports have suggested the prognostic value and survival benefit for metastasectomy in lesions that are amenable to complete resection after longer disease-free intervals in carefully selected patients with adequate performance status. Therefore, the role of metastasectomy must be further elucidated in the era of targeted therapy.

AB - Numerous biological pathways are affected in renal cell carcinoma and the introduction of targeted agents has improved the survival of patients with advanced and metastatic disease. Durable and long-lasting cure is rarely achieved, and in select cases, the excision of metastatic deposits has shown to increase survival. Clinical trials of targeted agents are being explored as neoadjuvant and adjuvant therapies with the role of metastasectomy evolving in the treatment paradigm. This review examines published reports of metastasectomy and its developing role in the era of targeted therapy. A Medline search was conducted using keywords "metastasectomy," "renal cell carcinoma," and "targeted therapy," and selected articles are discussed by examining prognostic stratification and metastasectomy in major anatomic regions. Most published reports span earlier periods of immunotherapy and chemotherapy, and henceforth, discussions are in historical context in this review. Although there is lack of Level 1 evidence, reports have suggested the prognostic value and survival benefit for metastasectomy in lesions that are amenable to complete resection after longer disease-free intervals in carefully selected patients with adequate performance status. Therefore, the role of metastasectomy must be further elucidated in the era of targeted therapy.

KW - Kidney cancer

KW - Metastasectomy

KW - Renal cell carcinoma

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84901343666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901343666&partnerID=8YFLogxK

U2 - 10.1007/s00345-014-1293-6

DO - 10.1007/s00345-014-1293-6

M3 - Article

C2 - 24744223

AN - SCOPUS:84901343666

VL - 32

SP - 631

EP - 642

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 3

ER -